12406 HORESHAM STREET, CARMEL, IN
Investor Presentation
Reports First Quarter 2026 Financial Results and Corporate Highlights
Annual Report to Security Holders
Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MBX Biosciences Enters Lease Agreement for New Office Space in Burlington, MA
Other Events
Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
Q1
FY 2025
Q3
Q2
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
S-1MEF